Bailey Dove/Victrelis

From Proteopedia

Victrelis

Victrelis (boceprevir) is an antiviral hepatitis C medication approved by the United States Food and Drug Administration in 2011. Victrelis is an inhibitor of the non-structural protein 3 (NS#) serine protease. The medication inhibits viral replication in Hepatitis C virus infected cells. ^[1]

References

1. ↑ Merck & Co., Inc. (n.d.) Highlights of prescribing information. Retrieved from https://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf
2. ↑ Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
3. ↑ Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
4. ↑ Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 2004 Feb;12(2):96-102. PMID:15036326 doi:http://dx.doi.org/10.1016/j.tim.2003.12.005
5. ↑ Centers for Disease Control and Prevention. (2015). Viral Hepatitis - Hepatitis C Information. Retrieved from http://www.cdc.gov/hepatitis/hcv/index.htm
6. ↑ Zhu Y, Chen S. Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. World J Gastroenterol. 2013 Dec 21;19(47):8963-73. doi: 10.3748/wjg.v19.i47.8963. PMID:24379621 doi:http://dx.doi.org/10.3748/wjg.v19.i47.8963
7. ↑ Robalino J, Browdy CL, Prior S, Metz A, Parnell P, Gross P, Warr G. Induction of antiviral immunity by double-stranded RNA in a marine invertebrate. J Virol. 2004 Oct;78(19):10442-8. PMID:15367610 doi:http://dx.doi.org/10.1128/JVI.78.19.10442-10448.2004

^{[1] [2] [3] [4] [5]}